A fresh perspective on the development of new drugs

Bringing Chemistry to Life

Visit https://thermofisher.com/bctl to register for your free Bringing Chemistry to Life T-shirt and https://www.thermofisher.com/chemistry-podcast/ to access the extended video version of this episode and the episode summary sheet, which contains links to recent publications and additional content recommendations for our guest.

You can access the extended video version of this episode via our YouTube channel to hear, and see, more of the conversation!

Antibiotics are an incredibly important class of drugs and possibly the most impactful, life-changing scientific innovation in history. However, microorganisms reproduce themselves very rapidly and can evolve in literal minutes. We can’t iterate science this quickly, which is the basis of increasing cases of antibiotic resistance that are a growing concern in modern medicine.

Antibiotics are complex both chemically and in their biological function, which makes them hard to develop and a relatively unattractive pharmaceutical class from the business perspective. Like never before, we need a fresh perspective, and this is where Ziyang Zhang is leaving an impression.

Ziyang is young, but incredibly productive and creative. Even before starting with his own research group (soon at Berkley), he has achieved so much and shown incredible chemical talent and thinking unlike anyone else’s. His new way of thinking can affect drug development strategies for antibiotics and beyond.

This is a captivating discussion with an incredible character, that fascinates with his understated style as he introduces us to his chemistry and his ideas. In a classic BCTL way, we explore his personal and professional path, his research into macrolide antibiotics, and his novel approach to selectively targeting brain cancer.

We read every email so please share your questions and feedback with us!

• Email [e-mail]

About Your Host

Born and raised in Italy, Paolo Braiuca, a PhD in pharmaceutical sciences, co-founded a startup company after conducting research in biocatalysis in Italy and the UK. He transitioned from R&D to business development, working in commercial, product management, and marketing roles in the specialty chemicals, biotechnology, and pharmaceutical markets in Germany and the UK. A busy father of four, if asked, he’ll call himself a “maker” at heart and enjoys inventing electronic devices in his free time.